Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study

A Pilot Study of 18F-FDG PET-CT Kinetic Analysis in Head and Neck Squamous Cell Carcinoma (HNSCC)

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02678884

Enrollment

Registered

2016-02-10

Start date

2014-10-31

Completion date

2028-11-30

Last updated

2024-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Squamous Cell Carcinoma

Keywords

Head and Neck Squamous Cell Carcinoma, Radiation therapy, Head and Neck Cancers

Brief summary

The purpose of this study is to see how useful the information provided from Positron Emission Tomography (PET) scans can be in the actual planning and delivery of radiation treatment to patients who have head and neck cancers. Patients participating in this study, will have (in addition to their routine tests) a PET scan before and during their radiation treatment. Following the intervention, patients will be followed as per standard practice.

Interventions

DRUG18-F FDG

All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Non-nasopharynx head and neck mucosal squamous cell carcinoma * Radiologically evident gross disease * Radiotherapy alone for curative intent * Age equal to or more than 18 years old * To be eligible for the second study PET-CT scan: FDG avid tumour (or minimum SUV of 2.5) on the first study PET-CT scan

Exclusion criteria

* Nasopharynx cancer * H&N SCC skin * Distant metastases (already known or if found on baseline CT-thorax) * Prior malignancy within the last 5 years (exclude non-H&N SCC, BCC skin) * Prior chemotherapy within the last 5 years or concurrent chemotherapy/EGFR inhibitors * Prior head and neck radiotherapy * Inability to lie supine for study duration * Pregnancy * Inability to provide informed consent

Design outcomes

Primary

Measure	Time frame
Measure rate constant of 18F-FDG uptake in tumour and normal tissue with dynamic PET scanning before radiotherapy.	~ 2 years

Secondary

Measure	Time frame
Measure rate constant of 18F-FDG uptake in tumour and inflammatory tissue with dynamic PET scanning during radiotherapy .	~ 2 years

Countries

Canada

Contacts

Primary ContactJohn J Kim, MD

John.kim@rmp.uhn.on.ca416 946 4501

Backup ContactStephen Breen, PhD

Stephen.Breen@rmp.uhn.on.ca416 946 4501

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026